7SMV

Crystallization of feline coronavirus Mpro with GC376 reveals mechanism of inhibition


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.93 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Crystallization of Feline Coronavirus M pro With GC376 Reveals Mechanism of Inhibition.

Lu, J.Chen, S.A.Khan, M.B.Brassard, R.Arutyunova, E.Lamer, T.Vuong, W.Fischer, C.Young, H.S.Vederas, J.C.Lemieux, M.J.

(2022) Front Chem 10: 852210-852210

  • DOI: https://doi.org/10.3389/fchem.2022.852210
  • Primary Citation of Related Structures:  
    7SMV, 7SNA

  • PubMed Abstract: 
  • Coronaviruses infect a variety of hosts in the animal kingdom, and while each virus is taxonomically different, they all infect their host via the same mechanism. The coronavirus main protease (M pro , also called 3CL pro ), is an attractive target for drug development due to its essential role in mediating viral replication and transcription ...

    Coronaviruses infect a variety of hosts in the animal kingdom, and while each virus is taxonomically different, they all infect their host via the same mechanism. The coronavirus main protease (M pro , also called 3CL pro ), is an attractive target for drug development due to its essential role in mediating viral replication and transcription. An M pro inhibitor, GC376, has been shown to treat feline infectious peritonitis (FIP), a fatal infection in cats caused by internal mutations in the feline enteric coronavirus (FECV). Recently, our lab demonstrated that the feline drug, GC373, and prodrug, GC376, are potent inhibitors of SARS-CoV-2 M pro and solved the structures in complex with the drugs; however, no crystal structures of the FIP virus (FIPV) M pro with the feline drugs have been published so far. Here, we present crystal structures of FIPV M pro -GC373/GC376 complexes, revealing the inhibitors covalently bound to Cys144 in the active site, similar to SARS-CoV-2 M pro . Additionally, GC376 has a higher affinity for FIPV M pro with lower nanomolar K i values compared to SARS-CoV and SARS-CoV-2 M pro . We also show that improved derivatives of GC376 have higher potency for FIPV M pro . Since GC373 and GC376 represent strong starting points for structure-guided drug design, determining the crystal structures of FIPV M pro with these inhibitors are important steps in drug optimization and structure-based broad-spectrum antiviral drug discovery.


    Organizational Affiliation

    Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
3C-like proteinaseA, B302Feline coronavirusMutation(s): 0 
EC: 3.4.19.12 (UniProt), 3.4.22 (UniProt), 2.7.7.48 (UniProt), 3.6.4.12 (UniProt), 3.6.4.13 (UniProt), 3.1.13 (UniProt), 4.6.1 (UniProt), 2.1.1.57 (UniProt)
UniProt
Find proteins for Q98VG9 (Feline coronavirus (strain FIPV WSU-79/1146))
Explore Q98VG9 
Go to UniProtKB:  Q98VG9
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ98VG9
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
UED (Subject of Investigation/LOI)
Query on UED

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide
C21 H31 N3 O5
JUCVXDDMQHPCKT-BZSNNMDCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.93 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 67.8α = 90
b = 77.42β = 90
c = 111.75γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Canadian Institutes of Health Research (CIHR)CanadaVR3-172655
Natural Sciences and Engineering Research Council (NSERC, Canada)Canada549297-2019

Revision History  (Full details and data files)

  • Version 1.0: 2022-04-06
    Type: Initial release